
	Where results make sense

Topic: Rituximab

Related Topics

Opsoclonus Myoclonus

In the News (Mon 21 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	MedlinePlus Drug Information: Rituximab Injection
		When rituximab is used to treat non-Hodgkin's lymphoma (NHL; a type of cancer that begins in a type of white blood cells that normally fight infection) it may cause a condition called tumor lysis syndrome (TLS; a group of symptoms caused by the fast breakdown of cancer cells).
		Rituximab is used alone or with other medications to treat certain types of non-Hodgkin's lymphoma (NHL; a type of cancer that begins in a type of white blood cells that normally fights infection).
		Rituximab is also used with another medication to treat the symptoms of rheumatoid arthritis (RA; a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in people who have already been treated with a certain type of medication called a tumor necrosis factor (TNF) inhibitor.
	www.nlm.nih.gov /medlineplus/druginfo/medmaster/a607038.html (1264 words)

	Rituximab
		Rituximab belongs to a group of medications known as monoclonal antibodies.
		Rituximab is used in combination with other chemotherapy medications to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
		Rituximab should be administered only under the supervision of a medical oncologist or hematologist.
	www.webmd.com /cancer/rituximab (526 words)

	Genentech: Products - Product Information - Rituxan Full Prescribing Information
		Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes.
		Rituximab was administered as loading doses on post-coitum days 20, 21 and 22, at 15, 37.5 or 75 mg/kg/day, and then weekly on post-coitum days 29, 36, 43 and 50, at 20, 50 or 100 mg/kg/week.
		Rituximab was excreted in the milk of lactating cynomolgus monkeys.
	www.gene.com /gene/products/information/oncology/rituxan/insert.jsp (8841 words)

	Rituximab (Mabthera®) : Cancerbackup
		Rituximab can also be given to some people with follicular lymphoma who have no signs of cancer at the end of their treatment (remission) to keep the lymphoma away.
		Rituximab locks onto a protein called CD20 which is found on the surface of one of the main types of normal white blood cells (B-cell lymphocytes).
		Rituximab is given as a drip (infusion) through a fine tube (cannula) inserted into the vein.
	www.cancerbackup.org.uk /Treatments/Biologicaltherapies/Monoclonalantibodies/Rituximab (1347 words)

	MedForumsLive.com - rituximab, Rituxan (Site not responding. Last check: )
		Rituximab is a man-made antibody that was developed using cloning and recombinant DNA technology from human and murine (mice or rat) genes.
		Rituximab is thought to attach to the CD20 receptor and cause the tumor cells to disintegrate (lyse).
		Since rituximab is an antibody that can be secreted into breast milk and absorbed by the infant, it has the potential for harming nursing infants.
	www.medforumslive.com /drugs/r/rituximab.html (680 words)

	rituximab Side Effects, Interactions and Information - Drugs.com
		Rituximab is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body.
		Rituximab is used in combination with other cancer medicines to treat non-Hodgkin's lymphoma.
		Rituximab is also used in combination with another drug called methotrexate to treat symptoms of adult rheumatoid arthritis.
	www.drugs.com /MTM/rituximab.html (1339 words)

	rituximab - Cancer Information (Cancers, Symptoms, Treatment) on MedicineNet.com
		Rituximab is a man-made antibody that was developed using cloning and recombinant DNA technology from human and murine (mice or rat) genes.
		Rituximab also is effective for treating rheumatoid arthritis and is used in patients that have failed other biologic medications, such as infliximab, etanercept, or adalimumab.
		Rituximab therapy is not recommended if there is an allergy to mice or rats since rituximab is made in mice or rats and may contain minute amounts of rat or mice proteins that can lead to severe allergic reactions.
	www.medicinenet.com /rituximab/article.htm (1039 words)

	Rituximab (Mabthera®) : CancerBACUP (Site not responding. Last check: )
		Rituximab can be given on its own to people who cannot have chemotherapy because of the potential side effects, or to those whose lymphoma has come back after chemotherapy.
		Rituximab locks on to a protein called CD20 which is found on the surface of one of the main types of normal white blood cells (B-cell lymphocytes).
		Rituximab is given as a drip (infusion) through a fine tube (cannula) inserted into the vein.
	www.cancerbacup.org.uk /Treatments/Biologicaltherapies/Monoclonalantibodies/Rituximab (880 words)

	Rituximab for Treatment of Intermediate and Aggressive B-cell Non-Hodgkin’s Lymphomas (Site not responding. Last check: )
		Rituximab is a recombinant, humanized monoclonal antibody directed against the CD20 antigen, a cell surface molecule expressed by B-lymphocytes and B-cell malignancies.
		In each biologics license, rituximab is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, B-cell non-Hodgkin’s lymphoma.
		This evidence is sufficient to permit conclusions on the outcomes of rituximab therapy for patients with intermediate/aggressive B-cell NHL.
	www.bcbs.com /tec/vol17/17_03.html (687 words)

	Hotline: May, 2006 - Abatacept and Rituximab
		Rituximab, a chimeric anti-CD20 monoclonal antibody was approved in 1997 for non-Hodgkin's lymphoma.
		Rituximab depletes B cells that have CD20 on their surface (including pre-B cells through mature B cells; but not stem cells or plasma cells) by several effector mechanisms.
		For rituximab, in the phase II study where MTX was withdrawn and rituximab monotherapy used in 1 group 4, it appeared that clinical responses to rituximab were not as long-lasting as in the group on combination rituximab plus MTX.
	www.rheumatology.org /publications/hotline/0506newdrugs.asp (2906 words)

	Rituximab: The RA Smart-Bomb
		Rituximab has already been proven to be of immense value in treating a variety of other diseases in which B cell activity plays a primary role, and its use in non-Hodgkin's lymphoma has revolutionized the current approach to treatment.
		Increasingly, rituximab has been utilized to deplete B cell populations in non-malignant diseases, especially those illnesses which have been designated autoimmune in nature.
		Now, based upon recent work which has implicated certain B cells in the destructive processes of rheumatoid arthritis, rituximab has been shown to be beneficial in lessening the destructive immune activity which is the basis of the disease.
	www.creakyjoints.com /go/article0061.shtml (346 words)

	Non-hodgkin's lymphoma - rituximab (No. 65)
		NICE has recommended that rituximab and the CHOP combination of chemotherapy medicines (a combination of cyclophosphamide, doxorubicin, vincristine and prednisolone) should be the first treatment considered for people with diffuse large-B-cell lymphoma that is at stage 2, 3 or 4.
		Rituximab is not recommended for people who are unable to have chemotherapy with the CHOP combination.
		NICE has said that rituximab should only be used in people with diffuse large-B-cell lymphoma in stage 1 if they are being treated as part of a clinical study.
	www.nice.org.uk /cat.asp?c=86763 (239 words)

	An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab -- Boye et al. 14 (4): 520 -- ...
		Rituximab ± CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) for previously untreated aggressive non-Hodgkin’s lymphoma: Overall survival [54].
		Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study.
		Rituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: a prospective trial in adults and children.
	annonc.oxfordjournals.org /cgi/content/full/14/4/520 (7541 words)

	Rituxan (Rituximab) drug description - FDA approved labeling for prescription drugs and medications at RxList
		The Rituxan® (Rituximab) antibody is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
		Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids (based on cDNA analysis) and has an approximate molecular weight of 145 kD.
		Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM.
	www.rxlist.com /cgi/generic/ritux.htm (416 words)

	Rituximab (Site not responding. Last check: )
		Rituximab can decrease the number of white blood cells in your body, cells that usually help you fight infections.
		Use reliable birth control while you are on rituximab and for at least 12 months after you stop treatment.
		Use condoms while you are on rituximab and for at least 12 months after you stop treatment.
	www.hci.utah.edu /patientdocs/hci/drugs/rituximab.htm (496 words)

	Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia -- Castagna et al. 102 (6): 2309 -- Blood (Site not responding. Last check: )
		Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
		Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
		Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
	www.bloodjournal.org /cgi/content/full/102/6/2309 (901 words)

	[No title]
		Rituximab for B-cell lymphoma In late 1997, rituximab became the first therapeutic monoclonal antibody approved by the FDA for the treatment of cancer.
		Rituximab is given as an intravenous infusion with a recommended dosing of 375 mg/m2 given once weekly for four doses.
		Rituximab for autoimmune diseases Based on the success of rituximab for the treatment of lymphoma, it was inevitable that it would soon be used to treat patients with a broader range of diseases involving B cells.
	cit.ucsd.edu /level2/forphys/spring2003.doc (1963 words)

	ACR: Rituximab Benefits Patients with Rheumatoid Arthritis (Site not responding. Last check: )
		Rituximab, a monoclonal antibody that targets the CD20 antigen on the surface of B-lymphocytes, is approved for use in CD20+ B-cell non-Hodgkin’s lymphoma.
		Infusions of both rituximab and cyclophosphamide were given within the first 17 days and all patients also received a 17-day course of corticosteroids.
		According to the researchers, all three rituximab regimens were well tolerated, with similar rates of adverse events.
	www.pslgroup.com /dg/221522.htm (452 words)

	News - Rituximab Effective for Tumor Necrosis Factor Nonresponders: Presented at ACR
		ACR 20 was achieved by 51% of the rituximab group and 18% of placebo subjects.
		ACR 50 was achieved by 27% of rituximab patients and 5% of placebo patients.
		The authors concluded that these results confirm rituximab is highly effective and well tolerated when given in combination with methotrexate in patients with active rheumatoid arthritis who have inadequate responses to 1 or more anti-TNF therapies.
	www.docguide.com /news/content.nsf/news/8525697700573E18852570BB005310BA (555 words)

	Extended rituximab therapy in Waldenstrom's macroglobulinemia -- Treon et al. 16 (1): 132 -- Annals of Oncology
		European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
		Rituximab for Waldenstrom's macroglobulinemia (E3A98): An ECOG phase II pilot study for untreated or previously treated patients.
		The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders.
	annonc.oxfordjournals.org /cgi/content/full/16/1/132 (3904 words)

	Lymphoma (follicular non-Hodgkin's) - rituximab (No. 37)
		Rituximab is recommended for the treatment of stage 3 or 4 follicular NHL when all other treatment options have been exhausted (that is, as a ‘last-line treatment’), and only on the understanding that the oncologist who prescribes it ensures that the effects of the drug on each patient are systematically recorded in a single listing.
		Rituximab is not recommended for patients with stage 3 or 4 follicular NHL for whom other treatments are still available – that is, in tiered stages of treatment, it is not recommended as a third-stage treatment (‘third-line treatment’) or later-stage treatment (‘subsequent-line treatment’).
		Summary: Guidance on the use of rituximab for recurrent or refractory Stage III or IV follicular non-Hodgkin's lymphoma
	www.nice.org.uk /cat.asp?c=29983 (304 words)

	Rituximab : BC Cancer Agency
		Rituximab (rye-TUX-im-ab) is a drug that is used to treat some kinds of lymphomas.
		Rituximab is a clear liquid that is injected slowly into a vein.
		It is not known if rituximab may harm the baby if used during pregnancy.
	www.bccancer.bc.ca /HPI/DrugDatabase/DrugIndexPt/Rituximab.htm (648 words)

	FDA Drug Safety Newsletter: Postmarketing Reviews
		Rituximab is a monoclonal antibody approved for the treatment of patients with non-Hodgkin's lymphoma and patients with moderate-to-severe, active rheumatoid arthritis when there has been inadequate response to other treatments.
		Rituximab is a powerful immunosuppressant that eliminates mature circulating B-cells for up to nine months.
		Four months after completing rituximab therapy, she was hospitalized with complaints of headache, nausea, vomiting, and pain.
	www.fda.gov /cder/dsn/2007_fall/postmarketing.htm (3133 words)

	Rituximab - National Cancer Institute
		Rituximab is approved by the Food and Drug Administration (FDA) to be used together with other drugs to treat certain types of non-Hodgkinâs lymphoma.
		Rituximab is also being studied in the treatment of other types of cancer and other conditions.
		FDA Approval for Rituximab - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
	www.cancer.gov /cancertopics/druginfo/rituximab (450 words)

	Clinical Trial: Rituximab to Treat Neuropathy with Anti-MAG Antibodies
		Rituximab is approved to treat B cell lymphomas.
		Although the number of patients treated with Rituximab was small, the drug was well tolerated and caused significant improvement in several of the patients.
		Rituximab is a monoclonal antibody specific for the common B cell antigen CD20.
	www.clinicaltrials.gov /ct/show/NCT00050245 (1133 words)

	NGC - NGC Summary
		Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical guideline
		There is currently insufficient evidence to support or refute the additional use of rituximab as a maintenance therapy in patients who have completed chemotherapy plus rituximab.
		Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline.
	www.guideline.gov /summary/summary.aspx?doc_id=7355&nbr=4353&ss=6&xl=999 (1025 words)

	New Data Suggest GM-CSF May Enhance Efficacy of Rituximab in Relapsed Follicular Lymphoma
		In the Phase 2 study, patients received a combination of rituximab and GM-CSF for four cycles of therapy.
		The complete response (CR) rate achieved with the combination therapy was 44 percent, and the overall response (OR) rate was 68 percent for the 33 intent-to-treat patients with relapsed FL.
		Typical CR achieved with monotherapy rituximab is 5-16 percent in relapsed follicular lymphoma.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-12-2005/0004231910&EDATE= (414 words)

	Optimizing Rituximab in B-Cell Lymphoma -- Horning 23 (6): 1056 -- Journal of Clinical Oncology
		rituximab and were subsequently re-treated weekly for 4 weeks.
		Witzig TE, Vukov AM, Habermann TM, et al: Rituximab therapy for patients with newly diagnosed, advanced-stage follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group.
		Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
	www.jco.org /cgi/content/full/23/6/1056 (2244 words)

	Rituxan (Rituximab) for Rheumatoid Arthritis and Non-Hodgkins Lymphoma
		Rituxan (Rituximab) for Rheumatoid Arthritis and Non-Hodgkins Lymphoma
		(rituximab) is indicated for the treatment of patients with:
		(rituximab) in combination with methotrexate is indicated to reduce signs and symptoms and to slow the progression of structural damage in adult patients with moderately-to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
	www.rituxan.com (426 words)

Try your search on: Qwika (all wikis)